Analyst firms · Oppenheimer · NRIX

Oppenheimer NRIX price target and rating history

Nurix Therapeutics Inc. (NRIX) · Health Care

Oppenheimer rates Nurix Therapeutics Inc. (NRIX) Outperform with a $28 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on NRIX since February 2023, including 0 upgrades and 0 downgrades. Across 3 firms with a NRIX price target in the last 12 months, the median target is $30. Oppenheimer's $28 is 7% below that.

Current rating
Outperform
Price target
$28
Median target, all firms
$30
Actions on NRIX
3

Oppenheimer price target on NRIX

$28$27$25202420252026
Oppenheimer price target on NRIX, each point a stated target, February 2023 to June 2026.

Every Oppenheimer rating on NRIX

How other firms rate NRIX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$28Jun 29, 2026
Morgan StanleyOverweight$36Jan 8, 2026
Truist SecuritiesBuy$30Nov 24, 2025

Questions about Oppenheimer and NRIX

What is Oppenheimer's price target for NRIX?
Oppenheimer's latest stated price target for Nurix Therapeutics Inc. (NRIX) is $28, from its action on Jun 29, 2026.
What is Oppenheimer's rating on NRIX?
Oppenheimer rates NRIX Outperform, a bullish rating, as of Jun 29, 2026.
When did Oppenheimer last change its view on NRIX?
On Jun 29, 2026, Oppenheimer resumes coverage at Outperform, price target $28.
How does Oppenheimer's NRIX target compare with other analysts?
Across 3 firms with a NRIX price target in the last 12 months, the median target is $30. Oppenheimer's $28 is 7% below that.

More NRIX rating histories

All Oppenheimer ratingsNRIX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.